Information Bulletin is available by fax, e-mail , and on our web site. There is no subscription fee to receive this bulletin, but please become a Network member if you have not already done so. Please let us know if you have any suggestions or comments about Network Bulletin. Amprenavir is not yet approved for prescription. An expanded access program is making amprenavir available to people who need new treatment options.
People can qualify for the expanded access program in several ways.
You can be enrolled in a trial if your current treatment is causing the side effect known as lipodystrophy . This trial will switch your current protease inhibitor to Agenerase, to see if the problem with fats goes away. If your combination treatment including a protease inhibitor is no longer working, you can enroll in a study of Agenerase taken with or without another protease inhibitor as part of a new anti-HIV drug combination. If your current treatment is no longer working and you need Agenerase to make a new combination, you may qualify for expanded access without taking part in a clinical trial. Due to the unforeseen high cost of the drug, some drug assistance programs have not been able to make Sustiva available right away.